Medimmune Limited

Robert E Hollingsworth

Ralph Raymond Minter

Melissa Marie Damschroder

Scott A Hammond

Lutz Jermutus

Sandrine Guillard

Ching Ching Leow

Carl Hay

Peter Pavlik

Erin Sult

Nicholas Durham

Kris Sachsenmeier

Qihui Huang

Gundo Diedrich

Jonathan Rios-Doria

Mary Antonysamy

James Geoghegan

Xiaojun Lu

Kim Rosenthal

Partha S Chowdhury

David Tice

Steven Rust

Steve Rust

Li Cheng

Martin Borrok, Iii

Chien-Ying Chang

Nabendu Pore

Emil F Michelotti

Martin J Iii Borrok

Partha Chowdhury

Iii Borrok Martin J

David A Tice

Lutz U Jermutus

Iii Martin J Borrok

This disclosure provides ASCT2-binding molecules, e.g., anti-ASCT2 antibodies, and antigen-binding fragments thereof. In certain aspects, the ASCT2-binding molecules are conjugated to cytotoxic drugs, e.g., ASCT2 antibody-drug conjugates (ADCs). In certain aspects, the anti-ASCT2 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects, the ASCT2-binding molecules bind specifically to cells expressing ASCT2, and in some instances, are internalized into the cells. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders characterized by ASCT2 overexpression, e.g., certain types of cancer. In a particular embodiment, the disclosure provides methods for treating cancer using ASCT2 ADCs.

Binding molecules specific for ASCT2 and uses thereof

The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

Binding molecules specific for CD73 and uses thereof

Growing community of inventors

Gaithersburg, MD, United States of America

Robert E Hollingsworth